Immuno-chemotherapy reduces recurrence of malignant pleural mesothelioma: an experimental setting

European Journal of Cardio-thoracic Surgery

Volumn 35, Issue 3, 2009, Pages 457-462

  Ampollini, Luca ^a   Soltermann, Alex ^a   Felley Bosco, Emanuela ^b   Lardinois, Didier ^a   Arni, Stephan ^a   Speck, Roberto F ^a   Weder, Walter ^a   Opitz, Isabelle ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b Laboratory of Molecular Oncology   (Switzerland)

Author keywords

Cisplatin; CpG ODN; Immunotherapy; Intrapleural; Mesothelioma; Toll like receptor

Indexed keywords

CISPLATIN; CPG OLIGODEOXYNUCLEOTIDE; FIBRIN GLUE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIVOSTAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOLOGY; CANCER INHIBITION; CANCER MODEL; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; IMMUNOHISTOCHEMISTRY; MALE; MALIGNANT MESOTHELIOMA; NONHUMAN; PRIORITY JOURNAL; RAT; RECURRENT CANCER; T LYMPHOCYTE SUBPOPULATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CISPLATIN; COMBINED MODALITY THERAPY; CYTOKINES; CYTOSINE; IMMUNOTHERAPY; INTERFERON-GAMMA; MALE; MESOTHELIOMA; NEOPLASM RECURRENCE, LOCAL; OLIGODEOXYRIBONUCLEOTIDES; PLEURAL NEOPLASMS; RANDOM ALLOCATION; RATS; RATS, INBRED F344; TOLL-LIKE RECEPTORS; TUMOR BURDEN; UP-REGULATION;

EID: 60849085160     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcts.2008.11.030     Document Type: Article

References (17)

1. Peto J., Decarli A., La Vecchia C., Levi F., and Negri E. The European mesothelioma epidemic. Br J Cancer 79 (1999) 666-672
2. Baris Y.I., and Grandjean P. Prospective study of mesothelioma mortality in Turkish villages with exposure to fibrous zeolite. J Natl Cancer Inst 98 6 (2006) 414-417
3. Weder W., Kestenholz P., Taverna C., Bodis S., Lardinois D., Jerman M., and Stahel R.A. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol 22 (2004) 3451-3457
4. Flores R.M., Pass H.I., Seshan V.E., Dycoco J., Zakowski M., Carbone M., Bains M.S., and Rusch V.W. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg 135 3 (2008) 620-626 626
5. Opitz I., Lardinois D., Arni S., Hillinger S., Vogt P., Odermatt B., Rousson V., and Weder W. Local recurrence model of malignant pleural mesothelioma for investigation of intrapleural treatment. Eur J Cardiothorac Surg 31 (2007) 772-778
6. Castagneto B., Zai S., Mutti L., Lazzaro A., Ridolfi R., Piccolini E., Ardizzoni A., Fumagalli L., Valsuani G., and Botta M. Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: results of a phase II study on 31 consecutive patients. Lung Cancer 31 (2001) 303-310
7. Seya T., Akazawa T., Tsujita T., and Matsumoto M. Role of toll-like receptors and their adaptors in adjuvant immunotherapy for cancer. Anticancer Res 23 (2003) 4369-4376
8. Grande C., Firvida J.L., Navas V., and Casal J. Interleukin-2 for the treatment of solid tumours other than melanoma and renal cell carcinoma. Anticancer Drugs 17 1 (2006) 1-12
9. Lucchi M., Chella A., Melfi F., Dini P., Ambrogi M., Fino L., Fontanini G., and Mussi A. A phase II study of intrapleural immuno-chemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II-III malignant pleural mesothelioma. Eur J Cardiothorac Surg 31 (2007) 529-535
10. van der Most R.G., Himbeck R., Aarons S., Carter S.J., Larma I., Robinson C., Currie A., and Lake R.A. Antitumour efficacy of the novel chemotherapeutic agent coramsine is potentiated by cotreatment with CpG-containing oligodeoxynucleotides. J Immunother 29 (2006) 134-142
11. Currie A.J., van der Most R., Broomfield S.A., Prosser A.C., Tovey M.G., and Robinson B.W.S. Targeting the effector site with IFN-αβ inducing TLR ligands reactives tumour-resident CD8 T cell response to eradicate established solid tumours. J Immunol 180 (2008) 1523-1544
12. Carpentier A.F., and Meng Y. Recent advances in immunotherapy for human glioma. Curr Opin Oncol 18 (2006) 631-636
13. Carpentier A.F., Auf G., and Delattre J.Y. CpG-oligonucleotides for cancer immunotherapy: review of the literature and potential applications in malignant glioma. Front Biosci 8 (2003) 115-127
14. Carpentier A.F., Mokhtari J.X.K., and Delattre J.Y. Successful Treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs. Clin Cancer Res 6 (2000) 2469-2473
15. Craighead J.E., Akley N.J., Gould L.B., and Libbus B.L. Characteristics of tumours and tumour cells cultured from experimental asbestos-induced mesotheliomas in rats. Am J Pathol 129 3 (1987) 448-462
16. Lagrelius M., Jones P., Franck K., and Gaines H. Cytokine detection by multiplex technology useful for assessing antigen specific cytokine profiles and kinetics in whole blood cultured up to seven days. Cytokine 33 3 (2006) 156-165
17. Lardinois D., Jung F.J., Opitz I., Rentsch K., Latkoczy C., Vuong V., Varga Z., Rousson V., Günther D., Bodis S., Stahel R., and Weder W. Intrapleural topical application of cisplatin with the surgical carrier Vivostat increases the local drug concentration in an immune-competent rat model with malignant pleuromesothelioma. J Thorac Cardiovasc Surg 131 (2006) 697-703